News | June 08, 2010

Continuing Warfarin Therapy is Safe for Patients Undergoing Surgery

June 8, 2010 – New study findings prove continuing warfarin therapy during pacemaker or defibrillator implantation in patients with moderate to high thromboembolic risk is safe and cost-effective. According to research published in the June edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, cessation of warfarin with bridging anticoagulation resulted in a higher incidence of bleeding complications and a longer hospital stay. In addition, patients with temporarily interrupted anticoagulation suffered from a higher risk of transient ischemic attacks (TIA) than those who continued warfarin therapy.

The retrospective study evaluated 459 patients on warfarin therapy and underwent antiarrhythmic device surgery from April 2004 to September 2008 at Regions Hospital, a major teaching affiliate of the University of Minnesota Medical School. During the perioperative period, three groups matched in age, sex and risk factors for thromboembolism were observed. The patient groups included continued warfarin therapy (48 percent), cessation of warfarin with heparin bridging therapy (26 percent) and temporarily interrupted anticoagulation without bridging therapy (24 percent).

Overall study findings revealed patients who continued taking warfarin had a lower incidence of bleeding and a shorter hospital stay. The incidence of pocket hematoma formation was 16-fold in patients on heparin bridging therapy when compared to the patient group on continued warfarin therapy. Furthermore, patients who continued treatment on warfarin experienced no TIAs after the procedure while risks were reported for the patients with interrupted anticoagulation without heparin bridging therapy (3.5 percent) and the bridging therapy group (0.8 percent).

“Because of concerns about excessive bleeding and potential associated complications, many clinicians temporarily hold warfarin therapy with or without bridging therapy with heparin or enoxaparin in patients preparing to undergo device implantation,” said lead author Dennis W. Zhu, M.D., director of cardiac electrophysiology laboratory at Regions Hospital, St. Paul, Minn. and an associate professor of medicine at University of Minnesota. “While temporarily holding the use of warfarin with or without bridging therapy is a common and accepted practice in many cases, our study shows that continuing warfarin is in fact more beneficial to these patients from a safety and cost stand point.”

Current guidelines recommend stopping oral anticoagulation and starting bridging therapy with heparin or enoxaparin in patients at moderate to high risk for thromboembolic events. However, this study reveals that continuing warfarin therapy is more beneficial and may impact future decisions on patient treatment to improve overall outcomes.

For more information:

Related Content

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve
News | Heart Valve Technology| August 22, 2017
August 22, 2017 — LivaNova PLC announced its Perceval ...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Overlay Init